Jul 9, 2018

Vaccine Maker PaxVax Tackles The Unmet Need Posed By Chikungunya Virus

PaxVax CEO Nima Farzan discusses PaxVax’s commitment to vaccine development to prevent against disease caused by the chikungunya virus and the company’s dedication to overcoming challenges along the way.

May 7, 2018

Vaccine for Chikungunya Prevention Gets Fast Track Designation

FDA grants PaxVax Fast Track designation for vaccine to prevent against disease caused by chikungunya virus.

Apr 18, 2018

Immigrant Ceos Beat The Curve When It Comes To Handling Turmoil: Study

PaxVax CEO Nima Farzan shares how his experiences as an immigrant have helped him be a more confident, motivated leader and CEO.

Aug 23, 2017

PaxVax’s Vaccine Platform & Other Research Build Momentum

PaxVax continues to evolve its approach for creating an HIV vaccine program, as the knowledge base and immune responses grow.

Jun 21, 2017

Nima Farzan Discusses Vaccine Development for Overlooked Infectious Diseases at BIO 2017

PaxVax seeks to develop vaccines for diseases that have been overlooked in markets that may not have as much commercial opportunity, but offer a great opportunity to make a social impact and a difference in people’s lives.

May 31, 2017

DoD Vaccine Research Saves Military, Civilian Lives

PaxVax works with the Walter Reed Army Institute of Research (WRAIR) to carry out the next human clinical trial for its chikungunya vaccine.

May 16, 2017

Lyon Leads Trial to Test Vaccine Aimed to Protect Military Troops

PaxVax is developing an important vaccine to fight adenovirus, a major cause of morbidity at military training centers, and Caroline Lyon, MD, MPH, is evaluating the safety and immunogenicity of the new vaccine.

Oct 31, 2016

We Need a Dose of Global Collaboration to Fight Zika

Progress is slow as industry players seek to develop a vaccine for Zika by working alone. PaxVax CEO, Nima Farzan, says global collaboration could help biotech and pharmaceutical companies combat outbreaks like Ebola and Zika before they become pandemics.

Jun 10, 2016

FDA Approves Cholera Vaccine for US Travelers

The FDA approves the PaxVax oral cholera vaccine for adults aged 18-64 who are traveling to countries affected by cholera.

May 17, 2016

Tackling Zika: Q&A With PaxVax CEO Nima Farzan

PaxVax CEO, Nima Farzan, says the company’s prior research and mission to address concerns of pandemic preparedness led to its decision to act quickly in developing a Zika candidate.

Mar 4, 2016

Vaccines 2016: Big Bets for Global Threats

PaxVax is among the array of companies working to develop a vaccine for Zika with hopes that it will help advance its social mission to positively impact the spread of infectious diseases in the developing world.

Feb 10, 2016

Zika Update: Vaccine Race Swells, PaxVax CEO on How to Stop ‘Chasing Epidemics’

Nima Farzan, PaxVax CEO, says the process for developing vaccines for neglected diseases could be more efficient if economic incentives were provided to biotech companies.